Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Deals

WuXi Biologics and GSK Ink Licensing Agreement for T-Cell Engaging Antibodies

Fineline Cube Jan 5, 2023

China-based WuXi Biologics (HKG: 2269) has announced a licensing agreement with GSK plc (NYSE: GSK),...

Company Deals

Antengene Acquires Full Rights to Calithera’s CD73 Inhibitor CB-708

Fineline Cube Jan 5, 2023

China-based Antengene Corporation Ltd (HKG: 6996) has unveiled a transfer agreement with US-headquartered Calithera Biosciences...

Company Drug

Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA

Fineline Cube Jan 5, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...

Company Deals

Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program

Fineline Cube Jan 5, 2023

Duality Biologics, a developer of novel modality drugs operating in the United States and China,...

Policy / Regulatory

NMPA Strengthens Oversight of COVID-19 Drugs and Home Treatment Guidelines

Fineline Cube Jan 5, 2023

The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality...

Company Medical Device

NMPA Approves Chinabridge’s ECMO Equipment for Emergency Use

Fineline Cube Jan 5, 2023

The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal...

Company Drug

EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer

Fineline Cube Jan 5, 2023

EOC Pharma, a biotech company operating in the US and China, has announced that its...

Company Deals

HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds

Fineline Cube Jan 5, 2023

China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...

Company Deals R&D

Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration

Fineline Cube Jan 5, 2023

US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...

Policy / Regulatory

China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan

Fineline Cube Jan 5, 2023

The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...

Company Deals

Zhongchao Partners with Natco Pharma to Distribute Drugs in China

Fineline Cube Jan 5, 2023

Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...

Company Deals

By-Health to Establish Nutrition Research Center with Shanghai Institute

Fineline Cube Jan 5, 2023

China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and...

Company Deals

CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA

Fineline Cube Jan 4, 2023

China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...

Company Drug

Transcenta’s TST003 Receives Clinical Trial Approval in China and US

Fineline Cube Jan 4, 2023

China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...

Company Drug

Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications

Fineline Cube Jan 4, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline

Fineline Cube Jan 4, 2023

China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...

Company Drug

HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP

Fineline Cube Jan 4, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...

Company Drug

RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...

Company Deals

Apeloa and Simcere Partner for CDMO Services and R&D Collaboration

Fineline Cube Jan 4, 2023

China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...

Company Deals

Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5

Fineline Cube Jan 4, 2023

China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...

Posts pagination

1 … 597 598 599 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.